BR0104830A - Tratamento de combinação para a demência ou déficits cognitivos associados com a doença de alzheimer e com a doença de parkinson - Google Patents
Tratamento de combinação para a demência ou déficits cognitivos associados com a doença de alzheimer e com a doença de parkinsonInfo
- Publication number
- BR0104830A BR0104830A BR0104830-9A BR0104830A BR0104830A BR 0104830 A BR0104830 A BR 0104830A BR 0104830 A BR0104830 A BR 0104830A BR 0104830 A BR0104830 A BR 0104830A
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- parkinson
- dementia
- cognitive deficits
- alzheimer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Patente de Invenção: "TRATAMENTO DE COMBINAçãO PARA A DEMêNCIA OU DéFICITS COGNITIVOS ASSOCIADOS COM A DOENçA DE ALZHEIMER E COM A DOENçA DE PARKINSON". A invenção presente refere-se a um método de tratar a demência ou os déficits cognitivos associados com a doença de Aizheimer ou com a doença de Parkinson, em um mamífero, incluindo em um ser humano, pela administração ao mamífero de um receptor de dopamina D4 em combinação com um inibidor de acetilcolina esterase. Também refere-se a composições farmacêuticas que contenham um veículo farmaceuticamente aceitável, um receptor de dopamina D4 e um inibidor de acetilcolina esterase.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24354300P | 2000-10-26 | 2000-10-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0104830A true BR0104830A (pt) | 2002-05-28 |
Family
ID=22919160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0104830-9A BR0104830A (pt) | 2000-10-26 | 2001-10-26 | Tratamento de combinação para a demência ou déficits cognitivos associados com a doença de alzheimer e com a doença de parkinson |
Country Status (6)
Country | Link |
---|---|
US (1) | US20020052373A1 (pt) |
EP (1) | EP1201268A3 (pt) |
JP (1) | JP2003063994A (pt) |
BR (1) | BR0104830A (pt) |
CA (1) | CA2359877A1 (pt) |
MX (1) | MXPA01010872A (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070053976A1 (en) * | 2002-05-17 | 2007-03-08 | Eisai R & D Management Co., Ltd. | Novel combination of drugs as antidepressant |
AU2003298514A1 (en) * | 2002-05-17 | 2004-05-04 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
JP2004123562A (ja) * | 2002-09-30 | 2004-04-22 | Japan Science & Technology Corp | 神経細胞死抑制作用を有する化合物を用いた医薬 |
CA2501547A1 (en) * | 2002-10-15 | 2004-04-29 | Rigel Pharmaceuticals, Inc. | Substituted indoles and their use as hcv inhibitors |
DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7049307B2 (en) | 2003-12-23 | 2006-05-23 | Abbott Laboratories | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
BRPI0518693A2 (pt) * | 2004-11-29 | 2008-12-02 | Warner Lambert Co | pirazol [3,4-b]piridinas e indazàis terapÊuticos, bem como composiÇço farmacÊutica e uso dos mesmos |
JPWO2007126041A1 (ja) * | 2006-04-28 | 2009-09-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ベンゾイソオキサゾール化合物 |
KR101408454B1 (ko) * | 2006-12-01 | 2014-06-17 | 닛토덴코 가부시키가이샤 | 도네페질 함유 접착 제제의 착색을 억제하는 방법 및 도네페질의 친척 물질의 생성량을 감소시키는 방법 |
KR101442286B1 (ko) * | 2006-12-01 | 2014-09-22 | 닛토덴코 가부시키가이샤 | 경피 흡수 제제 |
EP2078711A1 (en) * | 2007-12-28 | 2009-07-15 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. | (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor |
US8008327B2 (en) * | 2008-04-29 | 2011-08-30 | Boehringer Ingelheim International Gmbh | Indazole compounds as CCR1 receptor antagonists |
CA2722811C (en) * | 2008-05-06 | 2016-07-05 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
EP2279740A4 (en) * | 2008-05-30 | 2011-12-14 | Eisai R&D Man Co Ltd | TRANSDERMAL PREPARATION |
JP5208209B2 (ja) * | 2008-05-30 | 2013-06-12 | 日東電工株式会社 | ドネペジル含有貼付製剤およびその包装体 |
CN102227425A (zh) | 2008-09-26 | 2011-10-26 | 贝林格尔·英格海姆国际有限公司 | 作为ccr1受体拮抗剂的氮杂吲唑化合物 |
AU2010302584B2 (en) | 2009-10-02 | 2015-09-10 | Avexxin As | Anti inflammatory 2-oxothiazoles and 2 -oxooxazoles |
RS53130B (en) | 2009-10-21 | 2014-06-30 | Boehringer Ingelheim International Gmbh | INDASOL AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS |
EP2493875B1 (en) | 2009-10-27 | 2014-08-06 | Boehringer Ingelheim International GmbH | Heterocyclic compounds as ccr1 receptor antagonists |
EA201200820A1 (ru) * | 2009-12-08 | 2013-01-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ синтеза промежуточных продуктов, применимых для получения замещенных индазолов и азаиндазолов |
US8871786B2 (en) | 2010-04-30 | 2014-10-28 | Boehringer Ingelheim International Gmbh | Azaindazole amide compounds as CCR1 receptor antagonists |
WO2012087782A1 (en) | 2010-12-23 | 2012-06-28 | Boehringer Ingelheim International Gmbh | Pyrazolopiperidine compounds as ccr1 receptor antagonists |
KR102268357B1 (ko) | 2013-01-29 | 2021-06-23 | 아벡신 에이에스 | 항염증성 및 항종양성 2-옥소티아졸 및 2-옥소티오펜 화합물 |
WO2015157451A1 (en) * | 2014-04-08 | 2015-10-15 | Reviva Pharmaceuticals, Inc. | Methods for treating attention deficit hyperactivity disorder |
GB201413695D0 (en) | 2014-08-01 | 2014-09-17 | Avexxin As | Compound |
CN107206006A (zh) * | 2015-01-12 | 2017-09-26 | 雷维瓦药品公司 | 用于治疗与帕金森病相关联的精神病的方法 |
WO2016115144A1 (en) * | 2015-01-12 | 2016-07-21 | Reviva Pharmaceuticals Inc. | Methods for treating alzheimer's disease |
GB201604318D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
AU2023235233A1 (en) | 2022-03-14 | 2024-09-12 | Slap Pharmaceuticals Llc | Multicyclic compounds |
-
2001
- 2001-08-16 US US09/931,551 patent/US20020052373A1/en not_active Abandoned
- 2001-10-22 EP EP01308953A patent/EP1201268A3/en not_active Withdrawn
- 2001-10-24 CA CA002359877A patent/CA2359877A1/en not_active Abandoned
- 2001-10-25 MX MXPA01010872A patent/MXPA01010872A/es unknown
- 2001-10-26 BR BR0104830-9A patent/BR0104830A/pt not_active IP Right Cessation
- 2001-10-26 JP JP2001328863A patent/JP2003063994A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1201268A2 (en) | 2002-05-02 |
EP1201268A3 (en) | 2004-01-02 |
JP2003063994A (ja) | 2003-03-05 |
MXPA01010872A (es) | 2002-05-06 |
US20020052373A1 (en) | 2002-05-02 |
CA2359877A1 (en) | 2002-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0104830A (pt) | Tratamento de combinação para a demência ou déficits cognitivos associados com a doença de alzheimer e com a doença de parkinson | |
HK1087398A1 (en) | 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases | |
SI1509232T1 (sl) | Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni | |
TW200716208A (en) | Modified and immediate release memantine bead formulation | |
GB0421639D0 (en) | Methods and compositions relating to alzheimer's disease | |
WO2006001877A3 (en) | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen | |
WO2004071431A3 (en) | Method and composition for treating neurodegenerative disorders | |
EP1562897A4 (en) | PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER | |
DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
BRPI0512213A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
GB0223040D0 (en) | Therapeutic compounds | |
NO961326D0 (no) | Inhibitorer av | |
RS51540B (en) | MEMANTINE FOR THE TREATMENT OF Mild to Moderate Alzheimer's Disease | |
WO2001053457A3 (en) | Vaccines against neurodegenerative disorders | |
BR9914940A (pt) | Método para aperfeiçoar a farmacocinética de tipranavir | |
BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
BG105302A (en) | Means for improving cognition | |
WO2001058476A3 (en) | Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity | |
BRPI0413404A (pt) | composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif | |
BR0311903A (pt) | Tratamento para depressão e ansiedade pela combinação de um inibidor de pde iv e um agente antidepressivo ou ansiolìtico | |
WO2009043858A3 (en) | Methods for treating and diagnosing a cancer secreting cath-d or alzheimer's disease | |
BRPI0511305A (pt) | método de aliviar um granuloma anular ou sarcóide, artigo manufaturado e uso de um antagonista de lfa-1 | |
BR0111102A (pt) | Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4pip eridinometanol ou sua pró-droga no tratamento de sintomas de demência e psicose induzida por dopamina | |
WO2006020852A3 (en) | Pharmaceutical composition and method for treating neurodegenerative disorders | |
BRPI0509881A (pt) | combinação terapêutica para tratamento da doença de alzheimer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTEAO DESPACHO 8.6 DA RPI 2014 DE 11/08/2009. |